TrialPloS one2026

Using dapagliflozin to reduce symptoms in transthyretin cardiac amyloidosis: An n-of-1 trial series pilot study.

Erik Håkansson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.